These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 15291979)

  • 41. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
    Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR; Bonavida B
    Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biomarkers for personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The development and pharmacology of proteasome inhibitors for the management and treatment of cancer.
    Ruggeri B; Miknyoczki S; Dorsey B; Hui AM
    Adv Pharmacol; 2009; 57():91-135. PubMed ID: 20230760
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance.
    Maxwell SA; Mousavi-Fard S
    Exp Biol Med (Maywood); 2013 Sep; 238(9):971-90. PubMed ID: 23986223
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Non-Hodgkin's lymphoma of the central nervous system after treatment of Hodgkin's disease.
    Miller DC; Knee R; Schoenfeld S; Wasserstrom WR; Karp G
    Am J Clin Pathol; 1989 Apr; 91(4):481-5. PubMed ID: 2929506
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Editorial review: targets for glioma treatment: from bench to bedside.
    Sanson M
    Curr Opin Oncol; 2008 Nov; 20(6):650-1. PubMed ID: 18841046
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Secondary genomic alterations in non-Hodgkin's lymphomas: tumor-specific profiles with impact on clinical behavior.
    Beà S; Campo E
    Haematologica; 2008 May; 93(5):641-5. PubMed ID: 18450732
    [No Abstract]   [Full Text] [Related]  

  • 49. Altering protein turnover in tumor cells: new opportunities for anti-cancer therapies.
    Demarchi F; Brancolini C
    Drug Resist Updat; 2005 Dec; 8(6):359-68. PubMed ID: 16406769
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel treatment approaches for patients with multiple myeloma.
    Sinha R; Kaufman JL; Lonial S
    Clin Lymphoma Myeloma; 2006 Jan; 6(4):281-8. PubMed ID: 16507205
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recent Advances in the Discovery of Novel Peptide Inhibitors Targeting 26S Proteasome.
    Gu X; Ma S
    Anticancer Agents Med Chem; 2018; 18(12):1656-1673. PubMed ID: 30101718
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Thalidomide: dual benefits in palliative medicine and oncology.
    Davis MP; Dickerson ED
    Am J Hosp Palliat Care; 2001; 18(5):347-51. PubMed ID: 11565189
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel proteasome inhibitors to overcome bortezomib resistance.
    Ruschak AM; Slassi M; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expression of possible targets for new proteasome inhibitors in diffuse large B-cell lymphoma.
    Delforoush M; Berglund M; Edqvist PH; Sundström C; Gullbo J; Enblad G
    Eur J Haematol; 2017 Jan; 98(1):52-56. PubMed ID: 27301795
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Primary intramuscular non-Hodgkin's lymphoma in young subjects: about a case and review of the literature].
    Majdoul S; Omari N; Allali Y; Ghabri R; Benchakroun N; Fadili M; Tawfiq N; Jouhadi H; Sahraoui S; Nechad M; Benider A
    Pan Afr Med J; 2016; 25():223. PubMed ID: 28293339
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Proteasome inhibitors in cancer therapy: a novel approach to a ubiquitous problem.
    Landis-Piwowar KR
    Clin Lab Sci; 2012; 25(1):38-44. PubMed ID: 22458048
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [When to terminate the treatment of children with Hodgkin's disease, lymphoblastic leukemia and non-Hodgkin's lymphoma. Analysis of 80 cases].
    Armata J
    Pediatr Pol; 1979 Aug; 54(8):877-85. PubMed ID: 291888
    [No Abstract]   [Full Text] [Related]  

  • 58. Hodgkin's and non-Hodgkin's lymphomas.
    Rademaker J
    Radiol Clin North Am; 2007 Jan; 45(1):69-83. PubMed ID: 17157624
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Non-Hodgkin's lymphoma and acute myeloblastic leukemia: a report of 12 cases and review of the literature.
    Zarrabi MH; Rosner F; Bennett JM
    Cancer; 1979 Sep; 44(3):1070-80. PubMed ID: 383266
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Electrochemical assay for 20S proteasome activity and inhibition with anti-cancer drugs.
    Henriques de Jesus CS; Chiorcea-Paquim AM; Barsan MM; Diculescu VC
    Talanta; 2019 Jul; 199():32-39. PubMed ID: 30952265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.